Studies have shown that sirt1 is upregulated in many human cancer cell lines, as well as in tissues collected from patients suffering from various types of cancer (e.g., lung cancer, prostatic cancer, colon cancer, breast cancer, ovarian cancer, leukaemia, neuroblastomas, osteo-sarcomas, etc.), suggesting that sirtuins might be cancer therapeutic targets and the sirt1 inhibition in cancer cells could possibly inhibit cancer cell growth [143-145]. The gene discussed is SIRT1; the disease is prostate carcinoma.